A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel spiroindolone KAE609, to assess the safety, tolerability and pharmacokinetics in healthy adult volunteers

Samankaltaisia teoksia

• A First-in-Human Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Oral Dose Study of Novel Antimalarial Spiroindolone KAE609 (Cipargamin) To Assess Its Safety, Tolerability, and Pharmacokinetics in Healthy Adult Volunteers
  Tekijä: Leong, F. Joel, et al.
  Julkaistu: (2014)
• Spiroindolone KAE609 for Falciparum and Vivax Malaria
  Tekijä: White, Nicholas J., et al.
  Julkaistu: (2014)
• Pharmacokinetic-Pharmacodynamic Analysis of Spiroindolone Analogs and KAE609 in a Murine Malaria Model
  Tekijä: Lakshminarayana, Suresh B., et al.
  Julkaistu: (2015)
• A First-in-Human Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Oral Dose Study of Novel Imidazolopiperazine KAF156 To Assess Its Safety, Tolerability, and Pharmacokinetics in Healthy Adult Volunteers
  Tekijä: Leong, F. Joel, et al.
  Julkaistu: (2014)
• The Spiroindolone KAE609 Does Not Induce Dormant Ring Stages in Plasmodium falciparum Parasites
  Tekijä: Chavchich, Marina, et al.
  Julkaistu: (2016)